Custom service

Polyclonal Antibody Production

Broad epitope coverage, from a defined number of animals and bleeds.

Timeline: 8–12 weeks — to purified IgGTitre: ≥1:64,000 — by ELISA at final bleedHosts: Rabbit, goat, sheep — mouse and guinea pig on request

A polyclonal is a population, and its value lies in that population. Where a monoclonal commits to one epitope, a polyclonal recognises many, which gives it tolerance for slight sequence variation, for partial denaturation and for the conformational heterogeneity of a protein captured on a membrane or fixed in tissue.

Two animals, sometimes three, are immunised with 200–500 µg of antigen per injection over a ten- to twelve-week schedule. Serum titre is monitored from the second bleed onward, and the final production bleeds are taken only when the titre has plateaued at a level that justifies the animal's use. IgG is then purified by protein A/G affinity, or by antigen-affinity chromatography when the background from other serum antibodies matters.

The antibody you receive is a lot, not a clone. That has consequences worth stating: lot-to-lot variation is real, depletion of the animals ends the supply, and the reagent cannot be sequenced. For a diagnostic kit in development, those are reasons to switch to a recombinant monoclonal once the assay is defined.

Service Highlights

Where it fits

Polyclonals remain the pragmatic choice for Western blot, immunohistochemistry and immunoprecipitation of endogenous proteins, where epitope accessibility is unpredictable and a mixture of antibodies covers more of the antigen. They are also the fastest route to a working detection reagent when the target is a protein family rather than a single member.

They are a poor foundation for a quantitative sandwich assay or a diagnostic kit that must be reproducible over years. Where a defined, renewable reagent is required, a recombinant monoclonal or a hybridoma is the appropriate investment.

Documentation and QC

Each lot is released with an ELISA titration curve, total protein by A280, SDS-PAGE under reducing conditions, and endotoxin levels below 1 EU/mg. Application testing is reported as performed, including any background observed on the pre-immune serum at the same dilution.

Frequently asked questions

How much antibody will we receive?

A rabbit typically yields 80–150 mg of total IgG from a full production bleed, of which 5–20 mg is antigen-specific. Antigen-affinity purification delivers less total protein but a far higher specific fraction.

Can the same lot be produced again?

Not identically. Polyclonal sera vary between bleeds and between animals. If lot-to-lot consistency is required, we recommend generating a recombinant monoclonal from the same antigen.

Is an animal ethics approval needed?

The work is performed under an approved institutional animal protocol, and documentation is available for your file. We can also supply the immunisation schedule for your own ethics submission.

Tell us the application and the volume you need. If lot-to-lot consistency is likely to matter later, we will say so now rather than after the second bleed.

Service Highlights

  • Antigen-affinity option. Purification over an immobilised antigen column, which reduces background in IHC and in sandwich assays where serum proteins interfere.
  • Titre-driven bleeding. Production bleeds are taken when the ELISA titre supports them, not on a fixed calendar date.
  • Species matched to volume. Rabbit for 100–300 mg, goat and sheep for gram-scale requirements, with matched pre-immune serum.
  • Adjuvant selection. Freund's complete for the prime, incomplete thereafter, or RIBI and Montanide where injection-site reactions must be minimised.
  • Cross-reactivity screening. Tested against a panel of related proteins and, where relevant, against mouse, rat and human matrices.
  • Pre-immune control. Serum collected before the first injection is supplied with every lot, so background can be subtracted honestly.

How the work runs

  1. Antigen review

    Purity above 85% by SDS-PAGE and low endotoxin are prerequisites. Small antigens are conjugated to KLH, and the carrier response is removed during affinity purification.

  2. Immunisation schedule

    Prime with complete adjuvant, then three to four boosts at three-week intervals. Two to three animals per campaign, each bled and screened separately.

  3. Titre monitoring

    Test bleeds from week six, ELISA against the immunogen at serial dilutions. Animals that do not reach 1:16,000 by the second test bleed are boosted with an alternative formulation or replaced.

  4. Production bleeding

    Exsanguination or large-volume cardiac puncture under anaesthesia, with serum separated within four hours and stored at −80 °C in aliquots.

  5. Purification

    Protein A/G affinity as standard, antigen-affinity where specificity demands it, followed by buffer exchange into PBS and 0.22 µm filtration.

  6. QC and release

    Titre, total protein, SDS-PAGE, endotoxin and application-specific testing — Western blot, IHC or ELISA — before the lot is released.

Specifications & timeline

Timeline
8–12 weeks — to purified IgG
Titre
≥1:64,000 — by ELISA at final bleed
Hosts
Rabbit, goat, sheep — mouse and guinea pig on request
Timeline
8–12 weeks from antigen receipt to purified IgG
Host species
Rabbit, goat, sheep; mouse and guinea pig available
Antigen amount
1–3 mg total per campaign, depending on host
Serum volume
Rabbit 60–100 mL; goat 500–1,000 mL; sheep 500–1,000 mL
Purification
Protein A/G, antigen-affinity, or IgG depletion of carrier response
Deliverables
5–100 mg purified IgG, pre-immune serum, ELISA titration curve, SDS-PAGE, QC sheet

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.